{"drugs":["Jetrea","Ocriplasmin"],"mono":{"0":{"id":"930370-s-0","title":"Generic Names","mono":"Ocriplasmin"},"1":{"id":"930370-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930370-s-1-4","title":"Adult Dosing","mono":"<b>Vitreomacular adhesion, Symptomatic:<\/b> 0.125 mg (0.1 mL of diluted solution) via INTRAVITREAL INJECTION to the affected eye once as a single dose "},"1":{"id":"930370-s-1-5","title":"Pediatric Dosing","mono":"not recommended in pediatric patients "},"3":{"id":"930370-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Vitreomacular adhesion, Symptomatic<br\/>"}}},"3":{"id":"930370-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930370-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930370-s-3-10","title":"Precautions","mono":"<ul><li>dyschromatopsia, in some cases associated with electroretinographic changes, has been reported<\/li><li>intraocular inflammation, infection, and hemorrhage have been reported<\/li><li>intraocular pressure increases have been reported<\/li><li>lens subluxation has been reported with higher than recommended doses<\/li><li>retinal detachment and retinal tear, mostly occurring during or after vitrectomy, has been reported<\/li><li>visual acuity, decreased, has been reported; may indicate progression of condition; monitoring recommended<\/li><\/ul>"},{"id":"930370-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930370-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930370-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Ophthalmic:<\/b>Blurred vision (5% to 20%), Conjunctival hemorrhage (5% to 20%), Macular hole (5% to 20%), Pain in eye (5% to 20%), Photopsia (5% to 20%), Retinal edema (5% to 20%), Uveitis (7.1%), Visual impairment (5% to 20%), Vitreous floaters (5% to 20%)<br\/><b>Serious<\/b><br\/><b>Ophthalmic:<\/b>Cataract (2% to less than 5%), Degeneration of retina (2% to less than 5%), Reduced visual acuity (5% to 20%), Retinal detachment (0.4% to 0.9%), Retinal tear (up to 1.1%)<br\/>"},"6":{"id":"930370-s-6","title":"Drug Name Info","sub":{"0":{"id":"930370-s-6-17","title":"US Trade Names","mono":"Jetrea<br\/>"},"2":{"id":"930370-s-6-19","title":"Class","mono":"<ul><li>Ophthalmologic Agent<\/li><li>Proteolytic Enzyme<\/li><\/ul>"},"3":{"id":"930370-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930370-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930370-s-7","title":"Mechanism Of Action","mono":"Ocriplasmin, a truncated form of human plasmin with proteolytic activity against protein components of the vitreous body and the vitreoretinal interface, dissolves the protein matrix responsible for vitreomacular adhesion.<br\/>"},"8":{"id":"930370-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"930370-s-8-23","title":"Absorption","mono":"Tmax: immediately after injection <br\/>"},"2":{"id":"930370-s-8-25","title":"Metabolism","mono":"Rapidly via endogenous protein catabolism pathway <br\/>"}}},"9":{"id":"930370-s-9","title":"Administration","mono":"<b>Intravitreal<\/b><br\/><ul><li>allow vial to thaw to room temperature; add 0.2 mL NS and gently swirl<\/li><li>withdraw solution from vial with 19-gauge needle; replace with 30-gauge needle for administration<\/li><li>administer solution immediately after dilution, under controlled aseptic conditions with adequate anesthesia and broad spectrum microbicide<\/li><li>insert needle 3.5 to 4 mm posterior to limbus; avoid horizontal meridian; inject into mid-vitreous<\/li><li>intended for single use only; discard any unused product, use new vial, and change sterile field if contralateral eye also requires injection<\/li><\/ul>"},"10":{"id":"930370-s-10","title":"Monitoring","mono":"<ul><li>improvement in signs and symptoms of vitreomacular adhesion is indicative of efficacy.<\/li><li>decreased vision<\/li><li>intraocular pressure; immediately following administration<\/li><\/ul>"},"11":{"id":"930370-s-11","title":"How Supplied","mono":"<b>Jetrea<\/b><br\/>Intraocular Solution: 2.5 MG\/ML<br\/>"},"13":{"id":"930370-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn patient to use caution when doing activities requiring mental alertness or coordination, such as driving a car or operating heavy machinery until effects are known, as drug may cause visual impairment.<\/li><li>Drug may cause eye pain, blurred vision, visual impairment, and retinal edema.<\/li><li>Advise patient to immediately report signs\/symptoms of endophthalmitis or retinal detachment (ie, eye pain, eye redness, photophobia, blurred or decreased vision).<\/li><li>Instruct patient to immediately report signs\/symptoms of intraocular infection or inflammation including redness, pain, sensitivity to light, or changes in vision.<\/li><\/ul>"}}}